Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | The role of NGS and ctDNA in advancing personalized medicine in oncology

Klaus Pantel • 21 Oct 2023
ESMO 2023
General

Klaus Pantel, MD, PhD, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany, discusses the emerging role of next-generation sequencing (NGS) and liquid biopsies. Circulating tumor DNA (ctDNA) consists of DNA fragments released from the tumor detected in blood samples and detection of ctDNA can predict relapse and subsequently influence treatment options for individuals. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Klaus Pantel

The emerging role of MRD in solid tumor management
1:00
The emerging role of MRD in solid tumor management
Klaus Pantel • 21 Oct 2023
How can ctDNA analysis guide treatment in cancer?
0:48
How can ctDNA analysis guide treatment in cancer?
Klaus Pantel • 21 Oct 2023
Practical considerations for the use of liquid biopsies in lung cancer
1:32
Practical considerations for the use of liquid biopsies in lung cancer
Klaus Pantel • 27 Mar 2023
Liquid biopsies as a diagnostic tool in patients with lung cancer
2:13
Liquid biopsies as a diagnostic tool in patients with lung cancer
Klaus Pantel • 30 Mar 2023

Related Videos

Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026
The gut microbiome as a prognostic marker of side effects following radiotherapy
0:45
The gut microbiome as a prognostic marker of side effects following radiotherapy
Miguel Reis Ferreira • 16 May 2026
The content of VJOncology is intended for healthcare professionals